Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites

Journal of Virology

Volumn 79, Issue 7, 2005, Pages 4213-4218

  Bagossi, Péter ^a   Sperka, Tamás ^a   Fehér, Anita ^a   Kádas, János ^a   Zahuczky, Gábor ^a   Miklóssy, Gabriella ^a   Boross, Péter ^a   Tözsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; OLIGOPEPTIDE; PROLYLISOLEUCYLVALYLGLUTAMINE; PROTEINASE; UNCLASSIFIED DRUG; VALYLSERYLGLUTAMYLASPARAGYLTYROSINE;

AMINO ACID SUBSTITUTION; ARTICLE; AVIAN MYELOBLASTOSIS VIRUS; BINDING SITE; BOVINE LEUKEMIA VIRUS; ENZYME BINDING; ENZYME SPECIFICITY; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS; MASON PFIZER MONKEY VIRUS; MOLECULAR MODEL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SARCOMA VIRUS; SPUMA VIRUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AVIAN MYELOBLASTOSIS VIRUS; BINDING SITES; CONSERVED SEQUENCE; ELECTROSTATICS; EPSILONRETROVIRUS; HIV-1; HIV-2; HUMAN T-LYMPHOTROPIC VIRUS 1; HYDROPHOBICITY; INFECTIOUS ANEMIA VIRUS, EQUINE; LEUKEMIA VIRUS, BOVINE; MAMMARY TUMOR VIRUS, MOUSE; MASON-PFIZER MONKEY VIRUS; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PHYLOGENY; RETROVIRIDAE; SEQUENCE ALIGNMENT; SPUMAVIRUS; SUBSTRATE SPECIFICITY;

EID: 15244362933     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.7.4213-4218.2005     Document Type: Article

References (50)

1. Blaha, I., J. Tözsér, Y. Kim, T. D. Copeland, and S. Oroszlan. 1992. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase. FEBS Lett. 309:389-393.
2. Boross, P., P. Bagossi, T. D. Copeland, S. Oroszlan, J. M. Louis, and J. Tözsér. 1999. Effect of substrate residues on the P2′ preference of retroviral proteinases. Eur. J. Biochem. 264:921-929.
3. Cameron, C. E., B. Grinde, P. Jacques, J. Jentoft, J. Leis, A. Wlodawer, and I. T. Weber. 1993. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J. Biol. Chem. 268:11711-11720.
4. Chothia, C., and A. M. Lesk. 1986. The relation between the divergence of sequence and structure in proteins. EMBO J. 5:823-826.
5. Doyen, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
6. Dunn, B. M., A. Gustchina, A. Wlodawer, and J. Kay. 1994. Subsite preferences of retroviral proteinases. Methods Enzymol. 241:254-278.
7. Fehér, A., P. Boross, T. Sperka, S. Oroszlan, and J. Tözsér. 2004. Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expr. Purif. 35:62-68.
8. Fehér, A., I. T. Weber, P. Bagossi, P. Boross, B. Mahalingam, J. M. Louis, T. D. Copeland, I. Y. Torshin, R. W. Harrison, and J. Tözsér. 2002. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem. 269:4114-4120.
9. Felsenstein, J. 1989. PHYLIP-Phytogeny Inference Package. Cladistics 5: 164-166.
10. Fenyöfalvi, G., P. Bagossi, T. D. Copeland, S. Oroszlan, P. Boross, and J. Tözsér. 1999. Expression and characterization of human foamy virus proteinase. FEBS Lett. 462:397-401.
11. Fodor, S. K., and V. M. Vogt. 2002. Characterization of the protease of a fish retrovirus, walleye dermal sarcoma virus. J. Virol. 76:4341-4349.
12. Griffiths, J. T., L. H. Phylip, J. Konvalinka, P. Strop, A. Gustchina, A. Wlodawer, R. J. Davenport, R. Briggs, B. M. Dunn, and J. Kay. 1992. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. Biochemistry 31:5193-5200.
13. Gustchina, A., J. Kervinen, D. J. Powell, A. Zdanov, J. Kay, and A. Wlodawer. 1996. Structure of equine infectious anemia virus proteinase complexed with an inhibitor. Protein Sci. 5:1453-1465.
14. Kervinen, J., J. Lubkowski, A. Zdanov, D. Bhatt, B. M. Dunn, K. Y. Hui, D. J. Powell, J. Kay, A. Wlodawer, and A. Gustchina. 1998. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci. 7:2314-2323.
15. Louis, J. M., S. Oroszlan, and J. Tözsér. 1999. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J. Biol. Chem. 274:6660-6666.
16. Louis, J. M., I. T. Weber, J. Tözsér, G. M. Clore, and A. M. Gronenborn. 2000. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv. Pharmacol. 49:111-146.
17. MacArthur, M. W., and J. M. Thornton. 1991. Influence of proline residues on protein conformation. J. Mol. Biol. 218:397-412.
18. Mahalingam, B., P. Boross, Y. F. Wang, J. M. Louis, C. C. Fischer, J. Tözsér, R. W. Harrison, and I. T. Weber. 2002. Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins 48:107-116.
19. McCornack, M. A., L. T. Kakalis, C. Caserta, R. E. Handschumacher, and I. M. Armitage. 1997. HIV protease substrate conformation: modulation by cyclophilin A. FEBS Lett. 414:84-88.
20. Mellors, J. W. 1996. Closing in on human immunodeficiency virus-1. Nat. Med. 2:274-275.
21. Menendez-Arias, L., D. Gotte, and S. Oroszlan. 1993. Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 196:557-563.
22. Menendez-Arias, L., I. T. Weber, J. Soss, R. W. Harrison, D. Gotte, and S. Oroszlan. 1994. Kinetic and modeling studies of subsites S4-S3′ of Moloney murine leukemia virus protease. J. Biol. Chem. 269:16795-16801.
23. Menendez-Arias, L., M. Young, and S. Oroszlan. 1992. Purification and characterization of the mouse mammary tumor virus protease expressed in Eschenchia coli. J. Biol. Chem. 267:24134-24139.
24. Oroszlan, S., and R. B. Luftig. 1990. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157:153-185.
25. Pettit, S. C., J. Simsic, D. D. Loeb, L. Everitt, C. A. Hutchison III, and R. Swanstrom. 1991. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J. Biol. Chem. 266:14539-14547.
26. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.
27. Ridky, T., and J. Leis. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
28. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:779-815.
29. Schechter, I., and A. Berger. 1967. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:157-162.
30. Swanstrom, R., and J. Eron. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
31. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
32. Tomasselli, A. G., and R. L. Heinrikson. 1994. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:279-301.
33. Tong, L., S. Pav, S. Mui, D. Lamarre, C. Yoakim, P. Beaulieu, and P. C. Anderson. 1995. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure 3:33-40.
34. Tözsér, J., P. Bagossi, I. T. Weber, T. D. Copeland, and S. Oroszlan. 1996. Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J. Biol. Chem. 271:6781-6788.
35. Tözsér, J., P. Bagossi, I. T. Weber, J. M. Louis, T. D. Copeland, and S. Oroszlan. 1997. Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J. Biol. Chem. 272:16807-16814.
36. Tözsér, J., I. Blaha, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
37. Tözsér, J., D. Friedman, I. T. Weber, I. Blaha, and S. Oroszlan. 1993. Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry 32:3347-3353.
38. Tözsér, J., A. Gustchina, I. T. Weber, I. Blaha, E. M. Wondrak, and S. Oroszlan. 1991. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 279:356-360.
39. Tözsér, J., and S. Oroszlan. 2003. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr. Pharm. Des. 9:1803-1815.
40. Tözsér, J., I. T. Weber, A. Gustchina, I. Blaha, T. D. Copeland, J. M. Louis, and S. Oroszlan. 1992. Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases. Biochemistry 31:4793-4800.
41. Tözsér, J., G. Zahuczky, P. Bagossi, J. M. Louis, T. D. Copeland, S. Oroszlan, R. W. Harrison, and I. T. Weber. 2000. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Eur. J. Biochem. 267:6287-6295.
42. Vance, J. E., D. A. LeBlanc, P. Wingfield, and R. E. London. 1997. Conformational selectivity of HIV-1 protease cleavage of X-Pro peptide bonds and its implications. J. Biol. Chem. 272:15603-15606.
43. Vriend, G. 1990. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8:52-56.
44. Weber, I. T., J. Tözsér, J. Wu, D. Friedman, and S. Oroszlan. 1993. Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry 32:3354-3362.
45. Weiner, S. J., P. A. Kollman, D. T. Nguyen, and D. A. Case. 1986. An all atom force field for simulations of proteins and nucleic acids. J. Comput. Chem. 7: 230-252.
46. Wlodawer, A. 2002. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53:595-614.
47. Wu, J., J. M. Adomat, T. W. Ridky, J. M. Louis, J. Leis, R. W. Harrison, and I. T. Weber. 1998. Structural basis for specificity of retroviral proteases. Biochemistry 37:4518-4526.
48. Zabransky, A., M. Andreansky, O. Hruskova-Heidingsfeldova, V. Havlicek, E. Hunter, T. Ruml, and I. Pichova. 1998. Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. Virology 245:250-256.
49. Zahuczky, G., P. Boross, P. Bagossi, G. Emri, T. D. Copeland, S. Oroszlan, J. M. Louis, and J. Tözsér. 2000. Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. Biochim. Biophys. Acta 1478:1-8.
50. Zamyatin, A. A. 1972. Protein volume in solution. Prog. Biophys. Mol. Biol. 24:107-123.